Hualan Biological Vaccine Co., Ltd. 2025 Annual Report Assurance Report on the Use of Raised Funds
Dahua Audit [2026] No. 0011001480
To all shareholders of Hualan Biological Vaccine Co., Ltd.:
We have audited the attached Special Report on the Storage and Use of Raised Funds for 2025 of Hualan Biological Vaccine Co., Ltd. (hereinafter referred to as the "Special Report on Raised Funds").
I. Responsibility of the Board of Directors
The responsibility of the Board of Directors of Hualan Vaccine is to prepare the Special Report on Raised Funds in accordance with the "Supervisory Guidelines for Listed Companies No. 2 - Regulatory Requirements for the Management and Use of Raised Funds by Listed Companies (2022 Revision)" issued by the China Securities Regulatory Commission, the "Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 2 - Standardized Operation of GEM Listed Companies" issued by the Shenzhen Stock Exchange, and relevant format guidelines, and to ensure that its content is true, accurate, and complete, and does not contain any false records, misleading statements, or major omissions.
II. Responsibility of the Certified Public Accountants
Our responsibility is to express an assurance opinion on the Special Report on Raised Funds of Hualan Vaccine based on our assurance work. We performed the assurance engagement in accordance with the "Other Assurance Services Practice Standards of Chinese Certified Public Accountants No. 3101 - Assurance Engagements Other Than Audits or Reviews of Historical Financial Information." This standard requires us to plan and perform the assurance engagement to obtain reasonable assurance about whether the Special Report on Raised Funds of Hualan Vaccine is free from material misstatement.
During the assurance engagement, we performed procedures including obtaining an understanding, making inquiries, performing inspections, recalculating, and other procedures that we considered necessary. We believe that our assurance work provides a reasonable basis for our opinion.
III. Assurance Conclusion
We are of the opinion that the Special Report on Raised Funds of Hualan Vaccine has been prepared, in all material respects, in accordance with the "Supervisory Guidelines for Listed Companies" of the China Securities Regulatory Commission, the "Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 2 - Standardized Operation of GEM Listed Companies" issued by the Shenzhen Stock Exchange, and relevant format guidelines. In all material respects, it fairly reflects the situation of the storage, management, and use of raised funds by Hualan Vaccine in 2025.
IV. Limitation on the Users and Purpose of the Report
This report is intended solely for the purpose of disclosure in Hualan Vaccine's annual report and may not be used for any other purpose. We agree that this report will be an essential document for Hualan Vaccine's annual report and will be submitted and disclosed to the public along with other documents.
Dahua Certified Public Accountants (Special General Partnership)
Chinese Certified Public Accountant: [blank] (Signature) Lu Yongjun Lu Yongjun
Chinese Certified Public Accountant: [blank] (Signature) Zhu Honghui Zhu Honghui
March 27, 2026
Hualan Biological Vaccine Co., Ltd. 2025 Annual Report Special Report on the Storage and Use of Raised Funds
Hualan Biological Vaccine Co., Ltd. Special Report on the Storage and Use of Raised Funds for 2025
I. Basic Situation of Raised Funds
According to the approval document "Zheng Jian Xu Ke [2022] No. 2" from the China Securities Regulatory Commission and with the consent of the Shenzhen Stock Exchange, the company publicly issued 40.01 million shares of common stock (A shares) underwritten by Huatai United Securities Co., Ltd. on February 8, 2022, with a par value of RMB 1 per share and an issuance price of RMB 56.88 per share. As of February 14, 2022, the company raised a total of RMB 2,275,768,800.00. After deducting issuance expenses of RMB 31,565,696.07, the net amount of raised funds was RMB 2,244,203,103.93. Huatai United Securities Co., Ltd. remitted the amount after deducting the unpaid underwriting fees (including tax) of RMB 21,000,000.00 to the special account for raised funds of Hualan Vaccine on February 14, 2022, totaling RMB 2,254,768,800.00.